Abstract
A recent genome-wide association study identified seven single-nucleotide polymorphisms (SNPs) in region 16q24, near the Forkhead box-F1 (FOXF1) gene, which confer susceptibility to esophageal adenocarcinoma. We examined whether these SNPs are associated with clinical outcomes in gastric cancer (GC) patients in Japan and the United States. A total of 362 patients were included in this study: 151 Japanese GC patients treated with first-line S1 plus CDDP (training cohort) and 211 GC patients from Los Angeles County (LAC; validation cohort). Genomic DNA was isolated from whole blood or tumor tissue and analyzed by PCR-based direct DNA sequencing. Cox proportional hazard regression analyses were used to assess relationships between FOXF1 SNPs and progression-free survival (PFS) and overall survival (OS). FOXF1 rs3950627 was significantly associated with survival in both the training and validation cohorts. Japanese patients with the C/C genotype had a longer PFS (median 8.2 vs 5.3 months, hazard ratio (HR) 1.44, P=0.037) and OS (median 16.4 vs 12.2 months, HR 1.44, P=0.043) compared to patients with any A allele. Similarly, LAC patients with the C/C genotype had improved OS (3.9 vs 2.3 years, HR 1.5, P=0.022). Subgroup analyses showed these associations were specific to male patients and primary tumor subsite. Our findings suggest that FOXF1 rs3950627 might be a promising prognostic marker in GC patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ormestad M, Astorga J, Landgren H, Wang T, Johansson BR, Miura N et al. Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development 2006; 133: 833–843.
De Wever O, Demetter P, Mareel M, Bracke M . Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229–2238.
Mahlapuu M, Enerback S, Carlsson P . Haploinsufficiency of the forkhead gene Foxf1, a target for sonic hedgehog signaling, causes lung and foregut malformations. Development 2001; 128: 2397–2406.
Lo PK, Lee JS, Sukumar S . The p53-p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function. Cell Signal 2012; 24: 316–324.
Tamura M, Sasaki Y, Koyama R, Takeda K, Idogawa M, Tokino T . Forkhead transcription factor FOXF1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness. Oncogene 2014; 33: 4837–4846.
van den Brink GR, Hardwick JC, Tytgat GN, Brink MA, Ten Kate FJ, Van Deventer SJ et al. Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology 2001; 121: 317–328.
van den Brink GR, Hardwick JC, Nielsen C, Xu C, ten Kate FJ, Glickman J et al. Sonic hedgehog expression correlates with fundic gland differentiation in the adult gastrointestinal tract. Gut 2002; 51: 628–633.
Astorga J, Carlsson P . Hedgehog induction of murine vasculogenesis is mediated by Foxf1 and Bmp4. Development 2007; 134: 3753–3761.
Madison BB, McKenna LB, Dolson D, Epstein DJ, Kaestner KH . FoxF1 and FoxL1 link hedgehog signaling and the control of epithelial proliferation in the developing stomach and intestine. J Biol Chem 2009; 284: 5936–5944.
Saito RA, Micke P, Paulsson J, Augsten M, Pena C, Jonsson P et al. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res 2010; 70: 2644–2654.
Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M et al. Oestrogen receptor-alpha contributes to the regulation of the hedgehog signalling pathway in ERalpha-positive gastric cancer. Br J Cancer 2010; 102: 738–747.
Zhao XH, Gu SZ, Liu SX, Pan BR . Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues. World J Gastroenterol 2003; 9: 665–669.
Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet 2013; 45: 1487–1493.
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215–221.
Wu AH, Wan P, Bernstein L . A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001; 12: 721–732.
Watson JE, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, van Dekken H et al. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 2004; 23: 3487–3494.
Lo PK, Lee JS, Liang X, Han L, Mori T, Fackler MJ et al. Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res 2010; 70: 6047–6058.
Dura P, van Veen EM, Salomon J, te Morsche RH, Roelofs HM, Kristinsson JO et al. Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. Int J Cancer 2013; 133: 1751–1755.
Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G et al. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol 2011; 2: 77–84.
Chandanos E, Lagergren J . Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer 2008; 44: 2397–2403.
Sipponen P, Correa P . Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer 2002; 5: 213–219.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202–209.
Acknowledgements
Satoshi Matsusaka is a recipient of Takashi Tsuruo Memorial Fund. Stefan Stremitzer is a recipient of an Erwin Schrödinger fellowship of the Austrian Science Fund (J3501-B13). Martin D. Berger received a grant from the Swiss Cancer League (BIL KLS-3334-02-2014). The project described was supported in part by Award Number P30CA014089 from the National Cancer Institute.
Disclaimer
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. This project was also supported in part by the San Pedro Guild Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Presented in part at the American Society of Clinical Oncology Annual Meeting, 29 May–2 June, 2015, Chicago, IL, USA.
Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Matsusaka, S., Wu, A., Cao, S. et al. Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J 18, 262–269 (2018). https://doi.org/10.1038/tpj.2017.9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2017.9